GEOFFREY JEYASINGHAM: Open Payments
NPI 1124517404 · JEFFERSONVILLE, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,905 in 145 payments from 14 companies in 2025. Trend: 2023 $1,204 · 2024 $1,775 · 2025 $2,905
Food & beverage: $2,712Education: $193
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 36 | $860 |
| Alkermes, Inc. | 18 | $512 |
| Otsuka America Pharmaceutical, Inc. | 26 | $404 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 16 | $230 |
| ABBVIE INC. | 14 | $188 |
| Lundbeck LLC | 10 | $144 |
| Janssen Pharmaceuticals, Inc | 5 | $125 |
| Axsome Therapeutics, Inc. | 6 | $118 |
| E.R. Squibb & Sons, L.L.C. | 3 | $82 |
| Neurocrine BioSciences, Inc. | 3 | $67 |
Products named: UZEDY, ARISTADA, ABILIFY ASIMTUFII, REXULTI, CAPLYTA, VRAYLAR, LYBALVI, Auvelity.
Industry payments across IN — which companies pay providers there.
